Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 3 (2006), Issue 7 (July)

1. Gene transfer approaches for gynecological diseases.
   Mol Ther, 14(2): 154-63. [Abstract] [Full-text]
2. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
   Mol Ther, 14(2): 164-74. [Abstract] [Full-text]
3. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities.
   J Natl Cancer Inst, 98(13): 932-6. [Abstract] [Full-text]
4. Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube: a clinicopathologic study of 13 cases.
   Am J Surg Pathol, 30(7): 844-9. [Abstract] [Full-text]
5. Endometriosis mimicking advanced ovarian cancer.
   Fertil Steril, 86(1): 219.e23-5. [Abstract] [Full-text]
6. Early clinical detection of ovarian cancer: a review of the evidence.
   Expert Rev Anticancer Ther, 6(7): 1045-52. [Abstract] [Full-text]
7. Positron emission tomography in gynecological malignancies.
   Expert Rev Anticancer Ther, 6(7): 1033-44. [Abstract] [Full-text]
8. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
   JAMA, 296(2): 185-92. [Abstract] [Full-text]
9. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.
   Gynecol Oncol, 102(2): 140-4. [Abstract] [Full-text]
10. Splenectomy as part of cytoreductive surgery in ovarian cancer.
    Gynecol Oncol, 102(2): 369-74. [Abstract] [Full-text]
11. Palliative radiotherapy for recurrent granulosa cell tumor of the ovary: a report of 3 cases with radiological evidence of response.
    Gynecol Oncol, 102(2): 406-10. [Abstract] [Full-text]
12. Ovarian carcinoma with thyroid metastases causing clinical hypothyroidism: a case report.
    Gynecol Oncol, 102(2): 394-6. [Abstract] [Full-text]
13. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Gynecol Oncol, 102(2): 348-55. [Abstract] [Full-text]
14. Ovarian cancer metastatic to the breast.
    Gynecol Oncol, 102(2): 386-90. [Abstract] [Full-text]
15. Retrieval of intraperitoneal Penrose drain under transvaginal endoscopic guidance.
    Gynecol Oncol, 102(2): 391-3. [Abstract] [Full-text]
16. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.
    Gynecol Oncol, 102(2): 134-9. [Abstract] [Full-text]
17. Incidental diagnosis of struma ovarii after thyroidectomy for thyroid cancer: functional imaging studies and follow-up.
    Gynecol Oncol, 102(2): 378-80. [Abstract] [Full-text]
18. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Gynecol Oncol, 102(2): 285-91. [Abstract] [Full-text]
19. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
    Gynecol Oncol, 102(2): 270-7. [Abstract] [Full-text]
20. Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.
    Gynecol Oncol, 102(2): 338-42. [Abstract] [Full-text]
21. The fractionated Toona sinensis leaf extract induces apoptosis of human ovarian cancer cells and inhibits tumor growth in a murine xenograft model.
    Gynecol Oncol, 102(2): 309-14. [Abstract] [Full-text]
22. The role of maintenance therapy and novel taxanes in ovarian cancer.
    Gynecol Oncol, 102(2): 218-25. [Abstract] [Full-text]
23. Epigenetic regulation of maspin expression in human ovarian carcinoma cells.
    Gynecol Oncol, 102(2): 319-24. [Abstract] [Full-text]
24. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Gynecol Oncol, 102(2): 292-9. [Abstract] [Full-text]
25. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
    Gynecol Oncol, 102(2): 226-9. [Abstract] [Full-text]
26. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.
    Gynecol Oncol, 102(2): 300-8. [Abstract] [Full-text]
27. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
    Gynecol Oncol, 102(2): 244-51. [Abstract] [Full-text]
28. The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy.
    Gynecol Oncol, 102(2): 315-8. [Abstract] [Full-text]
29. Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer.
    Gynecol Oncol, 102(2): 204-9. [Abstract] [Full-text]
30. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
    Gynecol Oncol, 102(2): 236-9. [Abstract] [Full-text]
31. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.
    Cancer Gene Ther, 13(8): 732-8. [Abstract] [Full-text]
32. The importance of participation in support groups for women with ovarian cancer.
    Oncol Nurs Forum, 33(4): E53-61. [Abstract] [Full-text]
33. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary.
    J Surg Oncol, 94(2): 138-43. [Abstract] [Full-text]
34. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.
    Proc Natl Acad Sci U S A, 103(30): 11154-9. [Abstract] [Full-text]
35. The up-regulation profiles of p21WAF1/CIP1 and RUNX1/AML1 correlate with myometrial infiltration in endometrioid endometrial carcinoma.
    Hum Pathol, 37(8): 1050-7. [Abstract] [Full-text]
36. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas.
    Hum Pathol, 37(8): 1042-9. [Abstract] [Full-text]
37. Cytokeratin and CD30 expression in dysgerminoma.
    Hum Pathol, 37(8): 1015-21. [Abstract] [Full-text]
38. Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer.
    Clin Chem, 52(8): 1480-5. [Abstract] [Full-text]
39. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
    J Clin Oncol, 24(22): 3576-82. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.